Protective effects of KW-3902, a novel adenosine A1-receptor antagonist, against gentamicin-induced acute renal failure in rats

Jpn J Pharmacol. 1994 Jun;65(2):167-70. doi: 10.1254/jjp.65.167.

Abstract

We investigated the possible renal protective effects of KW-3902 (8-(noradamantan-3-yl)-1,3-dipropylxanthine), an adenosine A1-receptor antagonist, against gentamicin (GM)-induced acute renal failure (ARF) in rats. ARF was induced by subcutaneous injection of GM at 80 mg/kg/day for 12 days. KW-3902 (0.001-0.1 mg/kg, p.o., twice daily) attenuated the increases of serum creatinine and urea nitrogen and the decrease of creatinine clearance in rats treated with GM. In contrast, furosemide and trichlormethiazide aggravated the GM-induced nephrotoxicity. These results suggest that KW-3902 can ameliorate the GM-induced ARF and that endogenous adenosine may be involved in GM-induced ARF via the adenosine A1-receptor.

Publication types

  • Comparative Study

MeSH terms

  • Acute Kidney Injury / chemically induced
  • Acute Kidney Injury / drug therapy
  • Acute Kidney Injury / prevention & control*
  • Administration, Oral
  • Animals
  • Disease Models, Animal
  • Furosemide / administration & dosage
  • Furosemide / pharmacology
  • Furosemide / therapeutic use
  • Gentamicins / administration & dosage
  • Gentamicins / toxicity*
  • Injections, Subcutaneous
  • Kidney / drug effects*
  • Kidney / pathology
  • Male
  • Purinergic P1 Receptor Antagonists*
  • Rats
  • Rats, Wistar
  • Trichlormethiazide / administration & dosage
  • Trichlormethiazide / pharmacology
  • Trichlormethiazide / therapeutic use
  • Xanthines / administration & dosage
  • Xanthines / pharmacology
  • Xanthines / therapeutic use*

Substances

  • Gentamicins
  • Purinergic P1 Receptor Antagonists
  • Xanthines
  • rolofylline
  • Furosemide
  • Trichlormethiazide